Bone targeting agents: bisphosphonates

被引：11
作者：
Debiais, Francoise [1 ]
机构：
[1] Univ Poitiers, CHU Poitiers, Serv Rhumatol, F-86021 Poitiers, France
来源：
BULLETIN DU CANCER | 2013年 / 100卷 / 11期
关键词：
bone metastases; bisphosphonates; malignant osteolysis; CANCER ADJUVANT THERAPY; LONG-TERM EFFICACY; BREAST-CANCER; ZOLEDRONIC ACID; AMERICAN-SOCIETY; SOLID TUMORS; DOUBLE-BLIND; TASK-FORCE; METASTASES; PAMIDRONATE;
D O I：
10.1684/bdc.2013.1840
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Malignant tumor osteolysis is a frequent complication in many cancers. It can cause skeletal-related events with alteration of quality of life and survival. Bisphosphonates play an important role in the management of this malignant osteolysis, via an inhibition of osteoclast-mediated bone resorption, and a potential direct antitumor activity. Their use constitutes an important therapeutic advance in patients with bone metastases so as to reduce or delay the appearance of these skeletal events. They are also useful for the treatment of hypercalcemia, which could arise in these patients. Their interest as adjuvant therapy before the onset of bone metastases is currently being evaluated.
引用
收藏
页码：1199 / 1206
页数：8
相关论文
共 32 条
  • [1] Guidance on the use of bisphosphonates in solid tumours:: recommendations of an international expert panel
    Aapro, M.
    Abrahamsson, P. A.
    Body, J. J.
    Coleman, R. E.
    Colomer, R.
    Costa, L.
    Crino, L.
    Dirix, L.
    Gnant, M.
    Gralow, J.
    Hadji, P.
    Hortobagyi, G. N.
    Jonat, W.
    Lipton, A.
    Monnier, A.
    Paterson, A. H. G.
    Rizzoli, R.
    Saad, F.
    Thuerlimann, B.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 (03) : 420 - 432
  • [2] Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial
    Amadori, Dino
    Aglietta, Massimo
    Alessi, Barbara
    Gianni, Lorenzo
    Ibrahim, Toni
    Farina, Gabriella
    Gaion, Fernando
    Bertoldo, Francesco
    Santini, Daniele
    Rondena, Roberta
    Bogani, Paola
    Ripamonti, Carla I.
    [J]. LANCET ONCOLOGY, 2013, 14 (07) : 663 - 670
  • [3] [Anonymous], 2013, NCCN CLIN PRACT GUID
  • [4] [Anonymous], 2017, COCHRANE DB SYST REV
  • [5] [Anonymous], 2019, CLIN PRACTICE GUIDEL
  • [6] Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women
    Chlebowski, Rowan T.
    Chen, Zhao
    Cauley, Jane A.
    Anderson, Garnet
    Rodabough, Rebecca J.
    McTiernan, Anne
    Lane, Dorothy S.
    Manson, JoAnn E.
    Snetselaar, Linda
    Yasmeen, Shagufta
    O'Sullivan, Mary Jo
    Safford, Monika
    Hendrix, Susan L.
    Wallace, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) : 3582 - 3590
  • [7] Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
    Coleman, R.
    de Boer, R.
    Eidtmann, H.
    Llombart, A.
    Davidson, N.
    Neven, P.
    von Minckwitz, G.
    Sleeboom, H. P.
    Forbes, J.
    Barrios, C.
    Frassoldati, A.
    Campbell, I.
    Paija, O.
    Martin, N.
    Modi, A.
    Bundred, N.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (02) : 398 - 405
  • [8] Coleman RE, 2012, P AM SOC CLIN ONCOL, V30
  • [9] Breast-Cancer Adjuvant Therapy with Zoledronic Acid
    Coleman, Robert E.
    Marshall, Helen
    Cameron, David
    Dodwell, David
    Burkinshaw, Roger
    Keane, Maccon
    Gil, Miguel
    Houston, Stephen J.
    Grieve, Robert J.
    Barrett-Lee, Peter J.
    Ritchie, Diana
    Pugh, Julia
    Gaunt, Claire
    Rea, Una
    Peterson, Jennifer
    Davies, Claire
    Hiley, Victoria
    Gregory, Walter
    Bell, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (15) : 1396 - 1405
  • [10] Debiais F., 2008, REV RHUM, V75, P511
1234